Skip to content

Study · Animal study (in vivo) · mouse · 2018

9 results

Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.

Tølbøl KS, Kristiansen MN, Hansen HH, Veidal SS, Rigbolt KT, Gillum MP, Jelsing J, Vrang N, Feigh M

World journal of gastroenterology1 Jan 2018Cited by 122 (Europe PMC)

PMID29375204 (opens in a new tab)PMCIDPMC5768937 (opens in a new tab)DOI10.3748/wjg.v24.i2.179 (opens in a new tab)PepBankPUB-29375204
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese mice with biopsy-confirmed NASH (DIO-NASH), liraglutide reduced body weight.

    In plain wordsIn mice with diet-induced fatty liver disease (NASH), liraglutide reduced body weight.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight, DIO-NASH model
    Study

    mousen: not reported in source

    DIO-NASH mice
    Comparator
    Vehicle
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.2 mg/kg BID · subcutaneous · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Liraglutide and elafibranor, but not OCA, reduced body weight in both models.
    2 context sentences
    Summary · context
    Male wild-type C57BL/6J mice (DIO-NASH) and Lep ob/ob (ob/ob-NASH) mice were fed a diet high in trans-fat (40%), fructose (20%) and cholesterol (2%) for 30 and 21 wk, respectively.
    Summary · context
    The mice were kept on the diet and received vehicle, liraglutide (0.2 mg/kg, SC, BID), obeticholic acid (OCA, 30 mg/kg PO, QD), or elafibranor (30 mg/kg PO, QD) for eight weeks.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In ob/ob mice with biopsy-confirmed NASH, liraglutide reduced body weight.

    In plain wordsIn ob/ob mice with fatty liver disease (NASH), liraglutide reduced body weight.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight, ob/ob-NASH model
    Study

    mousen: not reported in source

    ob/ob-NASH mice
    Comparator
    Vehicle
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.2 mg/kg BID · subcutaneous · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Liraglutide and elafibranor, but not OCA, reduced body weight in both models.
    2 context sentences
    Summary · context
    Male wild-type C57BL/6J mice (DIO-NASH) and Lep ob/ob (ob/ob-NASH) mice were fed a diet high in trans-fat (40%), fructose (20%) and cholesterol (2%) for 30 and 21 wk, respectively.
    Summary · context
    The mice were kept on the diet and received vehicle, liraglutide (0.2 mg/kg, SC, BID), obeticholic acid (OCA, 30 mg/kg PO, QD), or elafibranor (30 mg/kg PO, QD) for eight weeks.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In DIO-NASH mice, liraglutide improved histological steatosis scores.

    In plain wordsIn mice with diet-induced fatty liver disease (NASH), liraglutide improved liver fat scores.

    Peptide
    Liraglutide
    Outcome
    DecreaseSteatosis score, DIO-NASH model
    Study

    mousen: not reported in source

    DIO-NASH mice
    Comparator
    Vehicle
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    0.2 mg/kg BID · subcutaneous · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Liraglutide improved steatosis scores in DIO-NASH mice only.
    2 context sentences
    Summary · context
    Male wild-type C57BL/6J mice (DIO-NASH) and Lep ob/ob (ob/ob-NASH) mice were fed a diet high in trans-fat (40%), fructose (20%) and cholesterol (2%) for 30 and 21 wk, respectively.
    Summary · context
    The mice were kept on the diet and received vehicle, liraglutide (0.2 mg/kg, SC, BID), obeticholic acid (OCA, 30 mg/kg PO, QD), or elafibranor (30 mg/kg PO, QD) for eight weeks.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In ob/ob-NASH mice, liraglutide did not improve steatosis scores; the improvement occurred in DIO-NASH mice only.

    In plain wordsIn ob/ob mice with fatty liver disease (NASH), liraglutide did not improve liver fat scores.

    Peptide
    Liraglutide
    Outcome
    No significant changeSteatosis score, ob/ob-NASH model
    Study

    mousen: not reported in source

    ob/ob-NASH mice
    Comparator
    Vehicle
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    0.2 mg/kg BID · subcutaneous · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Liraglutide improved steatosis scores in DIO-NASH mice only.
    2 context sentences
    Summary · context
    Male wild-type C57BL/6J mice (DIO-NASH) and Lep ob/ob (ob/ob-NASH) mice were fed a diet high in trans-fat (40%), fructose (20%) and cholesterol (2%) for 30 and 21 wk, respectively.
    Summary · context
    The mice were kept on the diet and received vehicle, liraglutide (0.2 mg/kg, SC, BID), obeticholic acid (OCA, 30 mg/kg PO, QD), or elafibranor (30 mg/kg PO, QD) for eight weeks.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In DIO-NASH and ob/ob-NASH mice, liraglutide did not reduce fibrosis severity; only elafibranor did.

    In plain wordsIn mice with fatty liver disease (NASH), liraglutide did not reduce liver scarring; only another drug, elafibranor, did.

    Peptide
    Liraglutide
    Outcome
    No significant changeFibrosis severity
    Study

    mousen: not reported in source

    DIO-NASH and ob/ob-NASH mice
    Comparator
    Vehicle
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    0.2 mg/kg BID · subcutaneous · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Elafibranor and OCA reduced histopathological scores of hepatic steatosis and inflammation in both models, but only elafibranor reduced fibrosis severity.
    2 context sentences
    Summary · context
    Male wild-type C57BL/6J mice (DIO-NASH) and Lep ob/ob (ob/ob-NASH) mice were fed a diet high in trans-fat (40%), fructose (20%) and cholesterol (2%) for 30 and 21 wk, respectively.
    Summary · context
    The mice were kept on the diet and received vehicle, liraglutide (0.2 mg/kg, SC, BID), obeticholic acid (OCA, 30 mg/kg PO, QD), or elafibranor (30 mg/kg PO, QD) for eight weeks.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In NASH mouse models, liraglutide reduced total liver fat.

    In plain wordsIn mice with fatty liver disease (NASH), liraglutide reduced total liver fat.

    Peptide
    Liraglutide
    Outcome
    DecreaseTotal liver fat
    Study

    mousen: not reported in source

    DIO-NASH and ob/ob-NASH mice
    Comparator
    Vehicle
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    0.2 mg/kg BID · subcutaneous · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Liraglutide and OCA reduced total liver fat
    2 context sentences
    Summary · context
    Male wild-type C57BL/6J mice (DIO-NASH) and Lep ob/ob (ob/ob-NASH) mice were fed a diet high in trans-fat (40%), fructose (20%) and cholesterol (2%) for 30 and 21 wk, respectively.
    Summary · context
    The mice were kept on the diet and received vehicle, liraglutide (0.2 mg/kg, SC, BID), obeticholic acid (OCA, 30 mg/kg PO, QD), or elafibranor (30 mg/kg PO, QD) for eight weeks.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In NASH mouse models, liraglutide reduced liver collagen 1a1 content.

    In plain wordsIn mice with fatty liver disease (NASH), liraglutide reduced a liver scarring marker, collagen 1a1.

    Peptide
    Liraglutide
    Outcome
    DecreaseCollagen 1a1 content
    Study

    mousen: not reported in source

    DIO-NASH and ob/ob-NASH mice
    Comparator
    Vehicle
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    0.2 mg/kg BID · subcutaneous · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Liraglutide and OCA reduced total liver fat, collagen 1a1, and galectin-3 content, driven by significant reductions in liver weight.
    2 context sentences
    Summary · context
    Male wild-type C57BL/6J mice (DIO-NASH) and Lep ob/ob (ob/ob-NASH) mice were fed a diet high in trans-fat (40%), fructose (20%) and cholesterol (2%) for 30 and 21 wk, respectively.
    Summary · context
    The mice were kept on the diet and received vehicle, liraglutide (0.2 mg/kg, SC, BID), obeticholic acid (OCA, 30 mg/kg PO, QD), or elafibranor (30 mg/kg PO, QD) for eight weeks.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In NASH mouse models, liraglutide reduced liver galectin-3 content.

    In plain wordsIn mice with fatty liver disease (NASH), liraglutide reduced a liver inflammation and scarring marker, galectin-3.

    Peptide
    Liraglutide
    Outcome
    DecreaseGalectin-3 content
    Study

    mousen: not reported in source

    DIO-NASH and ob/ob-NASH mice
    Comparator
    Vehicle
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    0.2 mg/kg BID · subcutaneous · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Liraglutide and OCA reduced total liver fat, collagen 1a1, and galectin-3 content, driven by significant reductions in liver weight.
    2 context sentences
    Summary · context
    Male wild-type C57BL/6J mice (DIO-NASH) and Lep ob/ob (ob/ob-NASH) mice were fed a diet high in trans-fat (40%), fructose (20%) and cholesterol (2%) for 30 and 21 wk, respectively.
    Summary · context
    The mice were kept on the diet and received vehicle, liraglutide (0.2 mg/kg, SC, BID), obeticholic acid (OCA, 30 mg/kg PO, QD), or elafibranor (30 mg/kg PO, QD) for eight weeks.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In NASH mouse models, liraglutide significantly reduced liver weight, which drove the reductions in liver fat, collagen 1a1 and galectin-3.

    In plain wordsIn mice with fatty liver disease (NASH), liraglutide reduced liver weight.

    Peptide
    Liraglutide
    Outcome
    DecreaseLiver weight
    Study

    mousen: not reported in source

    DIO-NASH and ob/ob-NASH mice
    Comparator
    Vehicle
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    0.2 mg/kg BID · subcutaneous · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Liraglutide and OCA reduced total liver fat, collagen 1a1, and galectin-3 content, driven by significant reductions in liver weight.
    2 context sentences
    Summary · context
    Male wild-type C57BL/6J mice (DIO-NASH) and Lep ob/ob (ob/ob-NASH) mice were fed a diet high in trans-fat (40%), fructose (20%) and cholesterol (2%) for 30 and 21 wk, respectively.
    Summary · context
    The mice were kept on the diet and received vehicle, liraglutide (0.2 mg/kg, SC, BID), obeticholic acid (OCA, 30 mg/kg PO, QD), or elafibranor (30 mg/kg PO, QD) for eight weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.